Filed under: Good news, Amgen Inc (AMGN), Options, Technical Analysis

Amgen (AMGN – option chain) shares are rising today after the company said this morning the Food and Drug Administration has agreed to a priority review for Denosumab, its new skeletal drug. The FDA will decide whether to approve the drug by November 18. If you think that the stock won’t fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on AMGN.

AMGN opened this morning at .46. So far today the stock has hit a low of .32 and a high of .76. As of 12:15, AMGN is trading at .00 up 0.83 (1.6%). The chart for AMGN looks bullish and S&P gives AMGN a positive 4 STARS (out of 5) buy ranking.

Continue reading Amgen’s Demosumab gets Priority FDA Review

Amgen’s Demosumab gets Priority FDA Review originally appeared on BloggingStocks on Mon, 19 Jul 2010 13:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments
















Amgen – Food and Drug Administration – BloggingStocks – AMGN – Technical analysis
BloggingStocks

The BP Oil disaster has brought home one very strong point, we need to change the way we power our lives, from the electricity that runs our homes to the what powers our vehicles we can no longer accept the dangers of an Oil based society.
What the BP disaster may also do is create an [...]
Live Stock Trading News | Equities, Forex, Gold, Silver and Oil Trading » News & Events